BioSpace News Archive

Drug Development

Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103

Krystal Biotech, Inc. announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase 1 (GEM-1) study.

June 24, 2019
·
10 min read
Deals

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock On June 24, 2019

Mirati Therapeutics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

June 24, 2019
·
4 min read
Business

New Partnership Will Focus on Spinning Out New Drug Companies, Digital Health

The technologies developed by LAB10x will be applied to generate and analyze “anonymized” patient data sets to improve patient outcomes and accelerate medical research and pharmaceutical R&D.

June 24, 2019
·
2 min read
·
Alex Keown
Business

“This is crazy!"—Top Scientists Condemn Russian’s Plan for CRISPR Babies

Two well-known scientists, Margaret Hamburg, co-chair of the WHO’s international advisory committee on human genome-editing, and Victor Dzau, president of the U.S. National Academy of Medicine, told STAT in separate interviews this weekend that they were extremely concerned about Denis Rebrikov’s plans.

June 24, 2019
·
4 min read
·
Mark Terry
Drug Development

Alnylam’s RNAi Therapeutic Onpattro Shows Sustained Treatment in hATTR Study

Data shows the long-term efficacy and tolerability as well as the continued ability of Onpattro to reverse or halt neuropathy progression.

June 24, 2019
·
2 min read
·
Alex Keown
Policy

WHO Removes Controversial Opioid Guidelines Following Scathing Congressional Report

In a statement, WHO said it was discontinuing two guidelines that have been in place since 2011 and 2012 “in light of new scientific evidence that has emerged since the time of their publication” regarding the dangers of opioid abuse.

June 24, 2019
·
4 min read
·
Alex Keown
MorphoSys Presents Primary Analysis Data from L-MIND Study of Tafasitamab (MOR208) in combination with Lenalidomide in r/r DLBCL at ICML 2019

MorphoSys AG presented data from the primary analysis of the ongoing single-arm phase 2 clinical trial known as L-MIND in an oral presentation at the 15th International Conference on Malignant Lymphoma in Lugano, Switzerland.

June 24, 2019
·
7 min read
Noxxon Announces Leading International Pharma To Evaluate NOX-A12 In New Indication

NOXXON Pharma N.V. announced that a leading international pharmaceutical company amongst the top-10 pharmaceutical companies by worldwide revenue[1] has signed an agreement with NOXXON for the purpose of evaluating NOX-A12 in a new indication, which will remain undisclosed for competitive reasons.

June 24, 2019
·
3 min read
Pharm Country

Enterin’s DEMET Study Enrolls First Patient With Parkinson’s Disease Dementia (PDD)

Enterin Inc., a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease, has enrolled the first patient in the DEMET study.

June 24, 2019
·
2 min read
Business

MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer

MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer.

June 24, 2019
·
6 min read